The New England Journal of Medicine JULY 18, 2011

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

Myron S. Cohen, Ying Q. Chen, Marybeth McCauley, Theresa Gamble, Mina C. Hosseinipour, Nagalingeswaran Kumarasamy, James G. Hakim, Johnstone Kumwenda, Beatriz Grinsztejn, Jose H.S. Pilotto, Sheela V. Godbole, Sanjay Mehendale, Suwat Chariyalertsak, Breno R. Santos, Ambrose Makhema, Karlene M. Campbell, Jonathan Wang, Susan E. Schechter, et al.

Source: View publication →

Bottom Line

The HPTN 052 trial established that early initiation of antiretroviral therapy (ART) in HIV-infected individuals significantly reduces the risk of sexual transmission of HIV to uninfected heterosexual partners by 96% compared to delayed treatment.

Key Findings

1. Early initiation of ART reduced the risk of linked HIV transmission to sexual partners by 96% (hazard ratio 0.04; 95% CI 0.01 to 0.16; P<0.001).

2. Among 1,763 couples, 28 linked transmissions occurred during the study; 27 were in the delayed ART arm and only one was in the early ART arm.

3. The single transmission in the early ART group occurred early in the course of treatment before viral suppression was achieved, suggesting high durability of protection once viral loads are suppressed.

4. Early ART also resulted in a 41% reduction in the risk of HIV-related clinical events among the infected participants.

Study Design

Design

RCT

Open-Label

Sample

1,763

Patients

Duration

1.7 yr

Median

Setting

Multicenter, international

Population HIV-serodiscordant heterosexual couples in which the HIV-infected partner had a CD4 count between 350 and 550 cells per cubic millimeter and had not previously received ART.

Intervention Immediate initiation of antiretroviral therapy in the HIV-infected partner upon study enrollment.

Comparator Delayed initiation of antiretroviral therapy in the HIV-infected partner until the CD4 count fell below 250 cells per cubic millimeter or the development of an AIDS-defining illness.

Outcome Linked HIV transmission to the uninfected partner and the occurrence of HIV-related clinical events in the infected partner.

Study Limitations

• The study primarily enrolled heterosexual couples, which may limit the direct generalizability of the findings to men who have sex with men (MSM).

• The delayed treatment arm was discontinued prematurely upon the recommendation of the Data and Safety Monitoring Board due to the overwhelming benefit of early treatment, shortening the timeframe for direct comparison.

• Adherence to ART is critical for the durability of the prevention effect, and the study setting provided intensive support that may not be mirrored in all real-world clinical environments.

Clinical Significance

This landmark study provided the definitive evidence for the 'Treatment as Prevention' (TasP) paradigm, fundamentally altering global HIV treatment guidelines by supporting the initiation of ART regardless of CD4 cell count, which is now the standard of care for both individual health and public health benefit.

Historical Context

Before HPTN 052, there was considerable scientific debate regarding whether ART could effectively block sexual transmission, and many international guidelines recommended waiting until CD4 counts fell below a certain threshold before initiating therapy. The trial provided the necessary empirical data to transition to universal test-and-treat strategies, a core pillar in current global efforts to end the HIV epidemic.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the biological mechanism by which early antiretroviral therapy (ART) reduces the risk of HIV-1 transmission to a seronegative partner?

Key Response

The primary mechanism is the suppression of viral replication, which leads to a decrease in the viral load in both the blood and genital secretions. Since the probability of HIV transmission is highly correlated with the concentration of the virus in genital fluids (semen or vaginal secretions), achieving an undetectable viral load through ART significantly minimizes the infectiousness of the individual.

Resident

In the context of the HPTN 052 results, how should a clinician advise an HIV-infected patient in a serodiscordant relationship regarding the timing of ART initiation if their CD4 count is currently 550 cells/mm³?

Key Response

Based on HPTN 052, ART should be initiated immediately. The study demonstrated that early ART (started at CD4 counts of 350-550) reduced transmission to partners by 96% compared to delayed ART. This clinical shift prioritizes 'Treatment as Prevention' (TasP) to protect the partner, even if the infected patient does not yet meet traditional CD4-based criteria for their own health.

Fellow

While HPTN 052 provided definitive evidence for heterosexual couples, why was it necessary to conduct follow-up studies like the PARTNER and Opposites Attract trials to establish the 'Undetectable = Untransmittable' (U=U) consensus for MSM populations?

Key Response

HPTN 052 was 97% heterosexual. Because the per-act risk of HIV transmission is significantly higher for receptive anal intercourse compared to vaginal intercourse, subspecialists required specific data to ensure that viral suppression was equally protective against the higher physiological risks associated with anal sex before the U=U message could be universally applied across all sexual practices.

Attending

Beyond the reduction in transmission, what were the key 'individual' health benefits observed in the early-ART group of HPTN 052, and how does this affect the 'Treat All' strategy?

Key Response

The early-ART group showed a 41% reduction in treatment-related clinical events, specifically a significant reduction in extrapulmonary tuberculosis. This evidence, combined with the prevention data, reinforced the 'Treat All' strategy by showing that early initiation benefits both the public (prevention) and the individual (reduced morbidity), regardless of baseline CD4 count.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

HPTN 052 utilized phylogenetic analysis to distinguish 'linked' from 'unlinked' transmissions. Explain why this methodological choice was critical for the study’s internal validity regarding ART efficacy.

Key Response

Phylogenetic analysis allows researchers to determine if the HIV strain in the newly infected partner is genetically similar to the strain in the index participant. If the strains are 'unlinked' (acquired from a third party outside the dyad), the infection cannot be attributed to a failure of the index's ART. Excluding unlinked infections provides a more accurate measure of the biological efficacy of ART in preventing transmission within a specific relationship.

Journal Editor

The HPTN 052 trial was terminated early for the prevention endpoint following a planned interim analysis by the DSMB. What are the ethical and statistical trade-offs associated with stopping a landmark trial before its scheduled completion?

Key Response

Statistically, stopping early can lead to an overestimation of the treatment effect (the 'winner's curse'). However, when the interim hazard ratio is as extreme as 0.04 (96% reduction) with high statistical significance (p < 0.001), the ethical obligation to provide the superior treatment to the control group (delayed-start arm) outweighs the need for more precise long-term data, as it would be unethical to allow preventable transmissions to continue for the sake of narrower confidence intervals.

Guideline Committee

How did the HPTN 052 study fundamentally alter the strength of recommendation for ART in serodiscordant couples within the WHO and DHHS guidelines?

Key Response

Prior to HPTN 052, guidelines often focused on the infected person's CD4 threshold for their own health. HPTN 052 provided the 'Level 1' evidence necessary to upgrade the recommendation to 'Strong' for immediate ART initiation in all serodiscordant couples to prevent transmission, regardless of CD4 count. This eventually informed the 'Treat All' recommendation now standard in WHO guidelines and DHHS Section on HIV/AIDS, moving the threshold from <350 or <500 to 'any' CD4 count.

Clinical Landscape

Noteworthy Related Trials

2015

START Trial

n = 4,685 · NEJM

Tested

Immediate antiretroviral therapy

Population

HIV-positive adults with CD4 counts >500 cells per cubic millimeter

Comparator

Deferred antiretroviral therapy

Endpoint

Composite of serious AIDS-related events, serious non-AIDS-related events, or death

Key result: Immediate ART initiation reduced the risk of serious AIDS and non-AIDS events by 57% compared to delaying treatment until CD4 count declined.

2015

TEMPRANO ANRS 12136 Trial

n = 2,056 · NEJM

Tested

Early initiation of antiretroviral therapy

Population

HIV-infected adults in Côte d'Ivoire with CD4 counts >500 cells per cubic millimeter

Comparator

Deferred antiretroviral therapy

Endpoint

Severe HIV-related morbidity or death

Key result: Early initiation of ART significantly reduced the risk of severe HIV-related illness compared to deferred treatment, regardless of the addition of isoniazid preventive therapy.

2016

PARTNER Study

n = 1,166 · JAMA

Tested

Antiretroviral therapy with viral suppression

Population

Serodifferent couples with HIV-positive partner on ART

Comparator

Unprotected sexual intercourse

Endpoint

Transmission of HIV to the negative partner

Key result: Zero linked HIV transmissions were observed among serodifferent couples having condomless sex when the HIV-positive partner had a suppressed viral load.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis